• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail
-

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Show All Studies
Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
General
Application Number P030025 S021
Current Protocol Accepted 09/24/2008
Study Name 5 year clinical outcomes
Study Status Completed
General Study Protocol Parameters
Study Design Randomized Clinical Trial
Study involve follow-up of premarket cohort (Y/N) Yes
Data Source Sponsor Registry
Comparison Group Historical Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description This was a prospective, randomized, controlled, multicenter, double-blind safety and efficacy study. Patients were randomized   show the rest ...
Study Population Description The device is indicated for improving luminal diameter for the treatment of de novo lesions   show the rest ...
Sample Size 1108 patients, 70 sites
Data Collection Primary endpoint for this study is the rate of ischemia-driven target vessel revascularization at 9   show the rest ...
Followup Visits and Length of Followup All patients were followed at 30 days, were to completed a 9-month follow-up evaluation, which   show the rest ...
Final Study Results
Actual Number of Patients Enrolled 1172 patients, 586 Control and 586 Taxus
Actual Number of Sites Enrolled 70 sites
Patient Followup Rate 83%
Final Safety Findings At the 5 year endpoint of the study, the TAXUS treatment group exhibited a statistically   show the rest ...
Study Strengths and Weaknesses Strengths: Five year clinical follow-up was completed in 83.1% of all patients enrolled and eligible   show the rest ...
Recommendations for Labeling Changes The high rates of MI and cardiac death or MI at five years in TAXUS   show the rest ...


5 year clinical outcomes Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Reporting Status
1 year report 09/24/2009 12/23/2008 On Time
2 year report 09/24/2010 10/30/2009 On Time

Show All Studies

-
-